Addressing the Unique Challenges of AD Patients
Patrick Burnett, MD, PhD, FAAD
PeerFDA Approves Ely Lilly’s AD Drug Ebglyss (Lebrikizumab)
ISDPA: Dr. Bhatia on JAK Inhibitors
Neal Bhatia, MD, FAAD
PeerISDPA: Dr. Bhatia and Dr. Zirwas Discuss the Itchy Patient
Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
Collagen in Atopic Dermatitis